EpilepsyGTx raises $33 million Series A to develop single dose gene therapy for focal refractory epilepsy
Investment from XGEN Venture, British Business Bank, and a global biopharmaceutical company will support first-in-human Phase 1/2a clinical trials for lead candidat...






















